Safety and efficacy of thrombin-JMI: A multidisciplinary expert group consensus

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 1, 2011, Pages 39-45

  Bhandari, Mohit ^a   Ofosu, Frederick A ^a   MacKman, Nigel ^b   Jackson, Craig ^c   Doria, Cataldo ^d   Humphries, John E ^e   Babu, Sateesh C ^f   Ortel, Thomas L ^g   Hoffman Van Thiel, David ^h   Walenga, Jeanine M ⁱ   Wahi, Rakesh ^j   Teoh, Kevin Hong To ^a   Fareed, Jawed ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Hemosaga Diagnostics Corp   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e Biologics Consulting Group Inc   (United States)

^f WESTCHESTER MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j Grant Memorial Hospital   (United States)

more..

Author keywords

bleeding; blood coagulation factors; hemostasis

Indexed keywords

RECOMBINANT THROMBIN;

ANEMIA; ARTICLE; BLEEDING; CONSTIPATION; DELPHI STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FEVER; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; INJURY; INSOMNIA; INTOXICATION; KIDNEY DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SCIENTIST; SIDE EFFECT; SKIN DISEASE; SURGEON; THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, TOPICAL; ANIMALS; AUTOANTIBODIES; CATTLE; CONSENSUS; DATA COLLECTION; FEMALE; HEMOSTASIS; HUMANS; MALE; SURGICAL PROCEDURES, OPERATIVE; THROMBIN;

EID: 78651383010     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610385674     Document Type: Article

References (13)

1. Lawson JH The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006 ; 32 (suppl 1). 98-110.
2. Clark J., Crean S., Reynolds MW Topical bovine thrombin and adverse events: a review of the literature. Curr Med Res Opin. 2008 ; 24 (7). 2071-2087.
3. Lundblad RL, Bradshaw RA, Gabriel D., Ortel TL, Lawson J., Mann KG A review of the therapeutic uses of thrombin. Thromb Haemost. 2004 ; 91 (5). 851-860.
4. Thrombin-JMI® [package insert]. Middleton, WI: GenTrac Inc ; 2007.
5. Linstone HA, Turoff M, eds. The Delphi Method: Techniques and Applications. Reading, MA: Addison-Wesley ; 1975: 291-321.
6. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods. 2003 ; 278 (1-2). 1-17.
7. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003 ; 18 (7). 1257-1259.
8. Schellekens H., Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004 ; 251 (suppl2). II/4 - II/9.
9. Chapman WC, Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ; 205 (2). 256-265.
10. Doria C., Fischer CP, Wood CG, Li PM, Marra S., Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008 ; 24 (3). 785-794.
11. Terrab A., Pawlak D., Spaay P., Hoppensteadt D., Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost. 2008 ; 14 (2). 135-140.
12. Ofosu FA, Crean S., Reynolds MW A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clin Ther. 2009 ; 31 (4). 679-691.
13. Clark JA, Humphries JE, Crean S., Reynolds MW Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. 2009 ; 19 (2). 107-114.